Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4 : possible fallout on non-medical switching
| Errataetall: |
CommentOn: Ann Rheum Dis. 2019 Feb;78(2):192-200. - PMID 30396903 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:79 |
|---|---|
| Enthalten in: |
Annals of the rheumatic diseases - 79(2020), 2 vom: 01. Feb., Seite e13 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cantini, Fabrizio [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-TNF |
|---|
| Anmerkungen: |
Date Completed 20.04.2020 Date Revised 20.04.2020 published: Print-Electronic CommentOn: Ann Rheum Dis. 2019 Feb;78(2):192-200. - PMID 30396903 Citation Status MEDLINE |
|---|
| doi: |
10.1136/annrheumdis-2018-214757 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM291181961 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM291181961 | ||
| 003 | DE-627 | ||
| 005 | 20231225070332.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/annrheumdis-2018-214757 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0970.xml |
| 035 | |a (DE-627)NLM291181961 | ||
| 035 | |a (NLM)30487149 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cantini, Fabrizio |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4 |b possible fallout on non-medical switching |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.04.2020 | ||
| 500 | |a Date Revised 20.04.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Ann Rheum Dis. 2019 Feb;78(2):192-200. - PMID 30396903 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a DMARDs (biologic) | |
| 650 | 4 | |a anti-TNF | |
| 650 | 4 | |a psoriatic arthritis | |
| 650 | 4 | |a rheumatoid arthritis | |
| 650 | 4 | |a spondyloarthritis | |
| 650 | 7 | |a Antirheumatic Agents |2 NLM | |
| 650 | 7 | |a Biosimilar Pharmaceuticals |2 NLM | |
| 650 | 7 | |a Etanercept |2 NLM | |
| 650 | 7 | |a OP401G7OJC |2 NLM | |
| 700 | 1 | |a Benucci, Maurizio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of the rheumatic diseases |d 1939 |g 79(2020), 2 vom: 01. Feb., Seite e13 |w (DE-627)NLM000174114 |x 1468-2060 |7 nnns |
| 773 | 1 | 8 | |g volume:79 |g year:2020 |g number:2 |g day:01 |g month:02 |g pages:e13 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/annrheumdis-2018-214757 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 79 |j 2020 |e 2 |b 01 |c 02 |h e13 | ||